Mymetics Receives Funding from NIH for Novel HIV Vaccine Study
Epalinges, Switzerland, April 29, 2019 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the National Institutes of Health (NIH) has awarded Mymetics and Texas Biomedical Research Institute (Texas Biomed) a five-year grant for the project called “Cold Chain-independent, Needle-free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels”.
| Media Name | Media Type | Description | Download |
|---|---|---|---|
| Press Release | Download |